Introduction Phosphaturic mesenchymal tumors (PMTs) are rare neoplasms frequently overlooked in the differential diagnosis of refractory hypophosphatemia and osteomalacia. Despite their clinical significance, a comprehensive synthesis of evidence on diagnostic accuracy, therapeutic outcomes, and prognostic factors remains lacking, with current literature fragmented across small case series and heterogeneous methodologies. This gap impedes the development of standardized clinical pathways for timely diagnosis and effective management.

Objective To systematically evaluate and meta-analyze the best available evidence on the clinicopathological features, diagnostic performance of imaging modalities, and treatment outcomes in patients with tumor-induced osteomalacia (TIO) secondary to PMTs.

Methods A PRISMA-compliant systematic review and meta-analysis was conducted across PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library. Peer-reviewed case series (≥3 patients) published in English were included. Data extraction focused on tumor localization, biochemical response, imaging accuracy, and surgical outcomes. Random-effects models were used for pooled estimates, with heterogeneity assessed via I2 and Cochran’s Q. Sensitivity and publication bias analyses ensured robustness.

Results Ten studies encompassing 1,176 patients were analyzed. Complete surgical resection yielded a high rate of biochemical remission, with consistent results across sensitivity analyses. □□Ga-DOTATATE PET/CT demonstrated superior diagnostic sensitivity compared to conventional modalities, significantly improving tumor localization. Methodological quality was moderate to high in most studies, and funnel plot symmetry indicated minimal publication bias.

Conclusion This meta-analysis confirms that early tumor localization with advanced functional imaging and complete resection are pivotal for curing TIO. A multidisciplinary approach integrating endocrinology, radiology, and surgical oncology is essential for optimal outcomes.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript